Current treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Progressive despite treatment Posts on Medivizor

Evaluating loncastuximab tesirine for patients with recurrent or hard-to-treat DLBCL

Evaluating loncastuximab tesirine for patients with recurrent or hard-to-treat DLBCL

Posted by on Jul 11, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of loncastuximab tesirine (Zynlonta) for patients with diffuse large B-cell lymphoma (DLBCL) that returned or stopped responding to treatment. This study concluded that this treatment was safe and effective for these patients. Some background DLBCL is one of the most common types of...

Read More

Evaluating the effectiveness of lenalidomide plus rituximab for patients with recurrent or hard-to-treat DLBCL

Evaluating the effectiveness of lenalidomide plus rituximab for patients with recurrent or hard-to-treat DLBCL

Posted by on Jul 11, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of lenalidomide (Revlimid) plus rituximab (Rituxan) for patients with diffuse large B-cell lymphoma (DLBCL) that came back or stopped responding to treatment. This study concluded that this treatment showed some effectiveness, but adding other agents may improve outcomes for these...

Read More

Sacituzumab govitecan improves survival in metastatic triple-negative breast cancer.

Sacituzumab govitecan improves survival in metastatic triple-negative breast cancer.

Posted by on Jun 12, 2021 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of sacituzumab govitecan (Trodelvy; SG) compared to chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer (mTNBC). The data showed that SG significantly improved the survival outcomes of these patients compared to chemotherapy. Some background...

Read More

Is CAR T-cell therapy more effective than salvage therapy for patients with DLBCL?

Is CAR T-cell therapy more effective than salvage therapy for patients with DLBCL?

Posted by on May 30, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the effectiveness of T-cell therapy to salvage chemotherapy in patients with recurrent or hard-to-treat diffuse large B-cell lymphoma (DLBCL). This study found that lisocabtagene maraleucel (liso-cel; Breyanzi) T-cell therapy was more effective than salvage chemotherapy for these patients. Some background DLBCL is one...

Read More

Searching for patients with solid tumors with abnormal genetic changes to trial an experimental medication

Searching for patients with solid tumors with abnormal genetic changes to trial an experimental medication

Posted by on Apr 30, 2021 in Colorectal cancer | 0 comments

In a nutshell This study is searching for participants with advanced solid tumors including colorectal cancer to examine the safety and effectiveness of experimental drug avapritinib (AYVAKIT). The main outcomes to be measured are the response to treatment and side effects. This trial is being conducted in Texas, US. The details Some cancers grow as a...

Read More

Evaluating the effectiveness and safety of inotuzumab ozogamicin for patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma

Evaluating the effectiveness and safety of inotuzumab ozogamicin for patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma

Posted by on Apr 18, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of inotuzumab ozogamicin (Besponsa; INO) in patients with relapsed/refractory (r/r) acute lymphocytic leukemia (ALL) and non-Hodgkin lymphoma (NHL). The data showed that the treatment had good effectiveness and manageable side effects for these patients. Some background A high number...

Read More

Evaluating the effectiveness and safety of inotuzumab ozogamicin for patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma

Evaluating the effectiveness and safety of inotuzumab ozogamicin for patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma

Posted by on Apr 18, 2021 in Leukemia | 0 comments

In a nutshell This study investigated the effectiveness and safety of inotuzumab ozogamicin (Besponsa; INO) in patients with relapsed/refractory (r/r) acute lymphocytic leukemia (ALL) and non-Hodgkin lymphoma (NHL). The data showed that the treatment had good effectiveness and manageable side effects for these patients. Some background A high number...

Read More

Comparing the safety and effectiveness of pyrotinib versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer

Comparing the safety and effectiveness of pyrotinib versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer

Posted by on Apr 18, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the safety and effectiveness of pyrotinib (SHR-1258) plus capecitabine (Xeloda) versus lapatinib (Tyverb) plus capecitabine in patients with metastatic human epidermal growth factor (HER2)-positive breast cancer (BC) after previous treatment with trastuzumab (Herceptin) and chemotherapy. The data...

Read More

How effective is umbralisib as treatment for patients with relapsed or refractory low-grade lymphoma?

How effective is umbralisib as treatment for patients with relapsed or refractory low-grade lymphoma?

Posted by on Apr 11, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors assessed the safety and effectiveness of umbralisib (Ukoniq) in patients with relapsed or refractory (r/r) indolent (low-grade) non-Hodgkin lymphoma (iNHL).   The study concluded that umbralisib was well tolerated and effective for patients with r/r iNHL. Some background iNHL is a slow-growing cancer of...

Read More

Evaluating outcomes of daratumumab, pomalidomide, and dexamethasone followed by high dose chemotherapy and ASCT for unresponsive multiple myeloma.

Evaluating outcomes of daratumumab, pomalidomide, and dexamethasone followed by high dose chemotherapy and ASCT for unresponsive multiple myeloma.

Posted by on Apr 4, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study aimed to investigate the effectiveness of DPd (daratumumab, pomalidomide, and dexamethasone) as salvage therapy followed by high dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) for relapsed/refractory (RR) multiple myeloma (MM). The study concluded that this therapy is effective and well tolerated...

Read More